{
    "body": "Could RG7112 be used as cancer therapy?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23400593", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24900694", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24812409", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23084521", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24579771", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21391905", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22753001"
    ], 
    "ideal_answer": [
        "Yes, RG7112 has shown promising results in early phases of trials in cancer patients."
    ], 
    "exact_answer": "yes", 
    "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:162"
    ], 
    "type": "yesno", 
    "id": "56ed0a372ac5ed1459000006", 
    "snippets": [
        {
            "offsetInBeginSection": 249, 
            "offsetInEndSection": 368, 
            "text": "RG7112 is a potent and selective member of the nutlin family of MDM2 antagonists currently in phase I clinical studies.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400593", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1389, 
            "offsetInEndSection": 1518, 
            "text": "Our findings offer a preclinical proof-of-concept that RG7112 is effective in treatment of solid tumors expressing wild-type p53.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400593", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 791, 
            "offsetInEndSection": 973, 
            "text": "On the other hand, JNJ-26854165, a novel tryptamine derivative and RG7112, a cis-imidazoline representative have shown promising results in early phases of trials in cancer patients.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21391905", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 118, 
            "text": "MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400593", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 968, 
            "offsetInEndSection": 1150, 
            "text": "On the other hand, JNJ-26854165, a novel tryptamine derivative and RG7112, a cis-imidazoline representative have shown promising results in early phases of trials in cancer patients.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21391905", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 176, 
            "text": "RG7112 is a selective inhibitor of p53-MDM2 binding that frees p53 from negative control, activating the p53 pathway in cancer cells leading to cell cycle arrest and apoptosis.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22753001", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 800, 
            "offsetInEndSection": 991, 
            "text": "In cancer cells expressing wild-type p53, RG7112 stabilizes p53 and activates the p53 pathway, leading to cell cycle arrest, apoptosis, and inhibition or regression of human tumor xenografts.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24900694", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 776, 
            "offsetInEndSection": 909, 
            "text": "Treatment of cancer cells expressing wild-type p53 with RG7112 activated the p53 pathway, leading to cell-cycle arrest and apoptosis.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400593", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 370, 
            "offsetInEndSection": 564, 
            "text": "RG7112 was selected for evaluation by the Pediatric Preclinical Testing Program (PPTP) due to the relatively low incidence of p53 mutations in pediatric cancers compared with adult malignancies.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22753001", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 648, 
            "offsetInEndSection": 780, 
            "text": "Treatment of cancer cells expressing wild-type p53 with RG7112 activated the p53 pathway, leading to cell-cycle arrest and apoptosis", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400593", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 791, 
            "offsetInEndSection": 972, 
            "text": "On the other hand, JNJ-26854165, a novel tryptamine derivative and RG7112, a cis-imidazoline representative have shown promising results in early phases of trials in cancer patients", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21391905", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 175, 
            "text": "RG7112 is a selective inhibitor of p53-MDM2 binding that frees p53 from negative control, activating the p53 pathway in cancer cells leading to cell cycle arrest and apoptosis", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22753001", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 117, 
            "text": "MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400593", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 615, 
            "offsetInEndSection": 805, 
            "text": "In cancer cells expressing wild-type p53, RG7112 stabilizes p53 and activates the p53 pathway, leading to cell cycle arrest, apoptosis, and inhibition or regression of human tumor xenografts", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24900694", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 177, 
            "offsetInEndSection": 370, 
            "text": "RG7112 was selected for evaluation by the Pediatric Preclinical Testing Program (PPTP) due to the relatively low incidence of p53 mutations in pediatric cancers compared with adult malignancies", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22753001", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 236, 
            "text": "We report a proof-of-mechanism study of RG7112, a small-molecule MDM2 antagonist, in patients with chemotherapy-naive primary or relapsed well-differentiated or dedifferentiated MDM2-amplified liposarcoma who were eligible for resection", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23084521", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 384, 
            "text": "BACKGROUND: RG7112 is a selective inhibitor of p53-MDM2 binding that frees p53 from negative control, activating the p53 pathway in cancer cells leading to cell cycle arrest and apoptosis. RG7112 was selected for evaluation by the Pediatric Preclinical Testing Program (PPTP) due to the relatively low incidence of p53 mutations in pediatric cancers compared with adult malignancies. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22753001", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 648, 
            "offsetInEndSection": 782, 
            "text": "Treatment of cancer cells expressing wild-type p53 with RG7112 activated the p53 pathway, leading to cell-cycle arrest and apoptosis. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400593", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 182, 
            "text": "Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23084521", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 189, 
            "offsetInEndSection": 384, 
            "text": "RG7112 was selected for evaluation by the Pediatric Preclinical Testing Program (PPTP) due to the relatively low incidence of p53 mutations in pediatric cancers compared with adult malignancies. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22753001", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 120, 
            "offsetInEndSection": 248, 
            "text": "Thus, inhibitors of p53-MDM2 binding that can reactivate p53 in cancer cells may offer an effective approach for cancer therapy.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400593", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 649, 
            "offsetInEndSection": 865, 
            "text": "Treatment of cancer cells expressing wild-type p53 with RG7112 activated the p53 pathway, leading to cell-cycle arrest and apoptosis. RG7112 showed potent antitumor activity against a panel of solid tumor cell lines.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400593", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 472, 
            "offsetInEndSection": 782, 
            "text": "A crystal structure of the RG7112-MDM2 complex revealed that the small molecule binds in the p53 pocket of MDM2, mimicking the interactions of critical p53 amino acid residues. Treatment of cancer cells expressing wild-type p53 with RG7112 activated the p53 pathway, leading to cell-cycle arrest and apoptosis.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400593", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 501, 
            "offsetInEndSection": 807, 
            "text": "RG7112 (2g) is the first clinical small-molecule MDM2 inhibitor designed to occupy the p53-binding pocket of MDM2. In cancer cells expressing wild-type p53, RG7112 stabilizes p53 and activates the p53 pathway, leading to cell cycle arrest, apoptosis, and inhibition or regression of human tumor xenografts.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24900694", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 178, 
            "offsetInEndSection": 524, 
            "text": "RG7112 was selected for evaluation by the Pediatric Preclinical Testing Program (PPTP) due to the relatively low incidence of p53 mutations in pediatric cancers compared with adult malignancies. RG7112 and its inactive enantiomer RG7112i were evaluated against the 23 cell lines of the PPTP in vitro panel using 96 hours exposure (1 nM to 10 \u00b5M).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22753001", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 121, 
            "offsetInEndSection": 369, 
            "text": "Thus, inhibitors of p53-MDM2 binding that can reactivate p53 in cancer cells may offer an effective approach for cancer therapy. RG7112 is a potent and selective member of the nutlin family of MDM2 antagonists currently in phase I clinical studies.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400593", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 616, 
            "offsetInEndSection": 810, 
            "text": "In cancer cells expressing wild-type p53, RG7112 stabilizes p53 and activates the p53 pathway, leading to cell cycle arrest, apoptosis, and inhibition or regression of human tumor xenografts.  .", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24900694", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 382, 
            "offsetInEndSection": 615, 
            "text": "Restoration of p53 activity by inhibiting the p53-MDM2 interaction may represent a novel approach to cancer treatment. RG7112 (2g) is the first clinical small-molecule MDM2 inhibitor designed to occupy the p53-binding pocket of MDM2.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24900694", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 178, 
            "offsetInEndSection": 524, 
            "text": "RG7112 was selected for evaluation by the Pediatric Preclinical Testing Program (PPTP) due to the relatively low incidence of p53 mutations in pediatric cancers compared with adult malignancies.RG7112 and its inactive enantiomer RG7112i were evaluated against the 23 cell lines of the PPTP in vitro panel using 96 hours exposure (1 nM to 10 \u00b5M).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22753001", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1298, 
            "offsetInEndSection": 1519, 
            "text": "Notably, RG7112 was highly synergistic with androgen deprivation in LNCaP xenograft tumors. Our findings offer a preclinical proof-of-concept that RG7112 is effective in treatment of solid tumors expressing wild-type p53.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400593", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1406, 
            "offsetInEndSection": 1642, 
            "text": "RG7112 induced tumor regressions in solid tumors from different histotype panels, and exhibited consistent high-level activity against ALL xenografts. This high level of activity supports prioritization of RG7112 for further evaluation.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22753001", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 372, 
            "text": "RG7112 is a selective inhibitor of p53-MDM2 binding that frees p53 from negative control, activating the p53 pathway in cancer cells leading to cell cycle arrest and apoptosis. RG7112 was selected for evaluation by the Pediatric Preclinical Testing Program (PPTP) due to the relatively low incidence of p53 mutations in pediatric cancers compared with adult malignancies.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22753001", 
            "endSection": "abstract"
        }
    ]
}